SEASTAR MEDICAL INC — Federal Contracts, Awards & Government Contractor Profile

About SEASTAR MEDICAL INC

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Their first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the FDA for the treatment of life-threatening acute kidney injury (AKI) in critically ill pediatric patients.

Patented Selective Cytopheretic Device (SCD) therapy that selectively targets highly activated neutrophils and monocytes responsible for destructive immune responsesSeamless integration into existing hemodialysis delivery systemsTreatment of acute kidney injury (AKI) in critically ill pediatric patients due to sepsis or septic-like conditionsConducting pivotal trials for adult patients with AKI requiring continuous renal replacement therapy

Is this your company?

Claim SEASTAR MEDICAL INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.

Claim SEASTAR MEDICAL INC & see your matches

Free to claim. Takes about a minute.

Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.